American College of Rheumatology

The oral selective inhibitor showed significant benefit versus placebo at 2 different doses in the phase 2b trial.

A new ACR 2021 study suggests patients on the biologic may be less likely to discontinue treatment than those receiving other drug classes.

New phase 3 data show TX-102 SL from Tonix may benefit central sensitization in patients afflicted with fibromyalgia pain.

A pandemic-era study suggests rheumatology care teams can capably provide beneficial care via telemedicine to treatment-stable patients.

New ACR findings suggest patients taking the common biologic drug closely leading up to their vaccination may not have a humoral response to it.

In this interview, Dr. Edigin speaks about his longitudinal trend analysis that showed a decrease in SLE flare hospitalizations over the last 20 years.

Favorable phase 2 results with the TYK2 inhibitor for psoriatic arthritis at ACR 2020 coincided with announced positive phase 3 trial results for psoriasis.

A secukinumab researcher explains why the practice may become the "next stethoscope" of medicine.

New findings show a unique series of markers could indicate particular black SLE patient risks.

A real-world study shows the therapy was slightly more efficacious for biologic-naive PsA patients.

A systematic review suggests patients taking immunosuppressive therapy may not be at as heightened risk of infection as previously thought.

An interview with a study author on the promising findings, and the use of ultrasonography in assessing psoriatic arthritis treatment.

Children hospitalized from the condition face a 14-fold increased risk of MACE.

The world is suddenly fixed on the field's most promising agents for an unprecedented virus. It's created a unique situation for specialists to collaborate.

The common rheumatic drug was found in a cohort analysis to be linked to greater regional TB outbreaks.

Less than 2% of surveyed families with rheumatic-disease children had reported a COVID-19 case in the early pandemic—and even fewer had physician-confirmed symptoms.

A discussion on how the pandemic has burdened and, in some ways, bettered the very involved specialty.

The monoclonal antibody has built on its 18-month portfolio with sustained renal benefits for the at-need patient group.

A new study contributes to the growing discussion around rheumatic disease treatment disparities.

Just 2% of observed older men to experience an indicative fracture received a diagnosis and treatment for osteoporosis over a four-year period.

New survey findings show the antimalarial drug's promotion for potential SARS-CoV-2 benefit early into the pandemic led to needing patients losing access.

An interview with a study author on implementing artificial intelligence into rheumatic care.

Data suggest patients administered tofacitinib for their arthritis do not face worsened risk, severity of flu infection.

The first 3 months of the pandemic were marked by a significant rate of patients changing or discontinuing medication without clinician guidance.

New data show patients with arthritis and psoriasis are far more likely to quarantine and isolate than similar patients, differentiating by treatment type.

New data from ACR 2020 assure concerns that patients with arthritis who test positive for COVID-19 may be at worse risk of ICU admission or even death.

Richard Furie, MD, chief of the division of rheumatology with Norwell Health, discusses the results of a phase 2 trial examining obinutuzumab for lupus nephritis.

Philip Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, discusses the current state of treatments for psoriatic arthritis.

Elaine Husni, MD, discusses the results of a trial she led examining quality of life changes in psoriatic arthritis patients receiving golimumab over a 1-year period.